SG11201503946UA - Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease - Google Patents

Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease

Info

Publication number
SG11201503946UA
SG11201503946UA SG11201503946UA SG11201503946UA SG11201503946UA SG 11201503946U A SG11201503946U A SG 11201503946UA SG 11201503946U A SG11201503946U A SG 11201503946UA SG 11201503946U A SG11201503946U A SG 11201503946UA SG 11201503946U A SG11201503946U A SG 11201503946UA
Authority
SG
Singapore
Prior art keywords
amelioration
prevention
treatment
viral disease
pyrimidone derivatives
Prior art date
Application number
SG11201503946UA
Other languages
English (en)
Inventor
Andrea Wolkerstorfer
Oliver Szolar
Norbert Handler
Helmut Buschmann
Stephen Cusack
Mark Smith
Sung-Sau So
Ronald Charles Hawley
Achyutharao Sidduri
Zhuming Zhang
Original Assignee
Savira Pharmaceuticals Gmbh
Hoffmann La Roche
European Molecular Biology Lab Embl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50070507&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201503946U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Savira Pharmaceuticals Gmbh, Hoffmann La Roche, European Molecular Biology Lab Embl filed Critical Savira Pharmaceuticals Gmbh
Publication of SG11201503946UA publication Critical patent/SG11201503946UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11201503946UA 2013-01-08 2014-01-07 Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease SG11201503946UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361750017P 2013-01-08 2013-01-08
PCT/EP2014/050165 WO2014108406A1 (en) 2013-01-08 2014-01-07 Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease

Publications (1)

Publication Number Publication Date
SG11201503946UA true SG11201503946UA (en) 2015-09-29

Family

ID=50070507

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201503946UA SG11201503946UA (en) 2013-01-08 2014-01-07 Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease

Country Status (21)

Country Link
US (1) US9045486B2 (https=)
EP (1) EP2943495B1 (https=)
JP (1) JP2016518305A (https=)
KR (1) KR20150103285A (https=)
CN (1) CN104918942A (https=)
AR (1) AR094378A1 (https=)
AU (1) AU2014204889A1 (https=)
BR (1) BR112015012693A2 (https=)
CA (1) CA2894642A1 (https=)
CL (1) CL2015001916A1 (https=)
CR (1) CR20150337A (https=)
EA (1) EA201591291A1 (https=)
HK (1) HK1211286A1 (https=)
IL (1) IL239656A0 (https=)
MA (1) MA38323B1 (https=)
MX (1) MX2015008293A (https=)
PE (1) PE20151722A1 (https=)
PH (1) PH12015501517A1 (https=)
SG (1) SG11201503946UA (https=)
TW (1) TW201443053A (https=)
WO (1) WO2014108406A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL239682B (en) 2013-01-08 2018-10-31 Kalvista Pharmaceuticals Ltd History of benzylamine and 2-(aminomethyl)pyridine
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
WO2015038655A1 (en) 2013-09-12 2015-03-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
WO2016145103A1 (en) 2015-03-11 2016-09-15 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
BR112017022550B1 (pt) 2015-04-28 2021-02-23 Shionogi & Co., Ltd derivados policíclicos de piridona substituída
MX394421B (es) 2015-04-28 2025-03-24 Shionogi & Co Derivados de piridona policiclica sustituida y profarmaco de los mismos
TW201726678A (zh) 2015-10-30 2017-08-01 赫孚孟拉羅股份公司 嘧啶酮衍生物及其於治療、改善或預防病毒性疾病之用途
AU2016374416A1 (en) 2015-12-15 2018-06-14 Shionogi & Co., Ltd. Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
WO2017109088A1 (en) 2015-12-23 2017-06-29 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
ES2881776T3 (es) 2016-03-08 2021-11-30 Novartis Ag Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus
WO2017158147A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017158151A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
JP6961963B2 (ja) * 2016-04-01 2021-11-05 三菱ケミカル株式会社 フルフラールの製造方法
EP3458455B1 (en) * 2016-05-20 2021-06-16 F. Hoffmann-La Roche AG Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases
IL263235B (en) 2016-05-31 2022-07-01 Kalvista Pharmaceuticals Ltd History of pyrazoles as plasma kallikrein inhibitors
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
RU2727962C1 (ru) 2016-08-10 2020-07-28 Сионоги Энд Ко., Лтд. Фармацевтические композиции, содержащие замещенные полициклические пиридоновые производные и их пролекарство
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
HUE057912T2 (hu) 2017-11-29 2022-06-28 Kalvista Pharmaceuticals Ltd Plazma kallikrein inhibitort tartalmazó dózisformák
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
KR20230031990A (ko) 2018-02-28 2023-03-07 노파르티스 아게 인플루엔자의 치료를 위한 오르토믹소바이러스 복제의 억제제로서의 10-(디(페닐)메틸)-4-히드록시-8,9,9a,10-테트라히드로-7h-피롤로[1',2':4,5]피라지노[1,2-b]피리다진-3,5-디온 유도체 및 관련 화합물
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
US20240228495A1 (en) * 2020-03-25 2024-07-11 Sri International Tricyclic Inhibitors of Influenza Virus Endonuclease
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
WO2024061300A1 (en) * 2022-09-22 2024-03-28 Insilico Medicine Ip Limited Inhibitors of trex1 and uses thereof
PE20251587A1 (es) 2022-10-19 2025-06-16 Astrazeneca Ab 1,3,5-triazinas 2,4,6-trisustituidas como modulares de cx3cr1

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475109A (en) 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
WO2005087766A1 (en) 2004-03-09 2005-09-22 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hiv integrase inhibitors
CN101014572B (zh) 2004-09-15 2011-07-06 盐野义制药株式会社 具有hiv整合酶抑制活性的氨基甲酰基吡啶酮衍生物
TW200716632A (en) 2005-05-16 2007-05-01 Gilead Sciences Inc Integrase inhibitor compounds
CA2616314A1 (en) * 2005-07-27 2007-02-01 Gilead Sciences, Inc. Antiviral phosphonate conjugates for inhibition of hiv
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
US8835461B2 (en) 2009-03-26 2014-09-16 Shionogi & Co., Ltd. Substituted 3-hydroxy-4-pyridone derivative
LT2444400T (lt) 2009-06-15 2018-06-11 Shionogi & Co., Ltd. Pakeistasis policiklinis karbamoilpiridono darinys
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
MX2013003139A (es) 2010-09-24 2013-06-18 Shionogi & Co Profarmaco de derivado de carbamoilpiridona policiclica substituida.

Also Published As

Publication number Publication date
CL2015001916A1 (es) 2016-01-22
MX2015008293A (es) 2016-06-02
HK1211286A1 (en) 2016-05-20
CR20150337A (es) 2015-11-02
AU2014204889A1 (en) 2015-06-11
EA201591291A1 (ru) 2015-12-30
EP2943495A1 (en) 2015-11-18
US9045486B2 (en) 2015-06-02
PH12015501517A1 (en) 2015-11-09
IL239656A0 (en) 2015-08-31
US20140194431A1 (en) 2014-07-10
MA38323A1 (fr) 2017-02-28
BR112015012693A2 (pt) 2017-07-11
AR094378A1 (es) 2015-07-29
EP2943495B1 (en) 2016-12-28
PE20151722A1 (es) 2015-11-19
KR20150103285A (ko) 2015-09-09
TW201443053A (zh) 2014-11-16
JP2016518305A (ja) 2016-06-23
HK1212686A1 (en) 2016-06-17
MA38323B1 (fr) 2018-05-31
CA2894642A1 (en) 2014-07-17
CN104918942A (zh) 2015-09-16
WO2014108406A1 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
IL239656A0 (en) Pyrimidone history and its use for the treatment, amelioration or prevention of viral disease
IL246564A (en) 3-aryl-1-heterocyclic-pyrazolo [4,3- d] pyrimidine derivatives and their use in the treatment of diseases
IL242610A0 (en) History of pyrazolopyrrolidine and their use in the treatment of diseases
BR112015002516A2 (pt) derivados de ácido carbônico di-hidroxipirimidina e seu uso no tratamento, melhora ou prevenção de doença viral.
ZA201507155B (en) Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders
GB2542155B (en) Use of cannabidiol in the treatment of mental disorders
IL240169A0 (en) Pyrimidine compositions for use in the treatment of diseases affected by ikke or tbk1 mechanisms
IL258979B (en) The use of pyrimidine and pyridine history in the treatment of cancer
PL3004112T3 (pl) Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
AP2016009219A0 (en) 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
PL3466425T3 (pl) Zastosowanie pochodnych glutarimidu w leczeniu chorób eozynofilowych
PT3004108T (pt) Derivados de pirazolo-pirrolidin-4-ona como inibidores de bet e a sua utilização no tratamento de doenças
IL250426A0 (en) 2'-Chloro aminopyrimidinone and pyridine dione nucleosides
IL239904A0 (en) Inhibitory oligonucleotides and their use in therapy
IL245738A0 (en) Oxindole derivatives, ways of their preparation and their therapeutic use in the treatment of ampk-related diseases
IL258682B (en) Viral neoepitopes and their uses
PL3010496T3 (pl) Arginina do zastosowania w leczeniu i/lub zapobieganiu chorobie zwyrodnieniowej stawów
GB2510477B (en) Formulations for use in the treatment of chronic fatigue and associated conditions, etc
HUE032883T2 (hu) Poliolok, elõállításuk és alkalmazásuk
HK1237343A1 (en) Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases
AP2015008849A0 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
IL251930B (en) Benzylhydroxy derivatives, their preparation and medical uses
ZA201600894B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes